ReproCELL Inc. (JP:4978)
:4978
Want to see JP:4978 full AI Analyst Report?
Top Page
ReproCELL Inc.
(4978)
Select Model
Select Model
Rating:42Neutral
Price Target:
¥122.00
▼(-14.69% Downside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by weak profitability and persistent cash burn despite a strong, low-debt balance sheet. Technicals also indicate a pronounced downtrend (below major moving averages with negative MACD), while valuation is constrained by losses (negative P/E) and no indicated dividend support.
Positive Factors
Very low leverage / strong equity buffer
ReproCELL’s virtually debt-free balance sheet and sizeable equity provide enduring financial flexibility, lowering solvency risk and enabling continued R&D and service operations without immediate refinancing needs. This structural capital buffer supports multi-quarter resilience during operational volatility.
Negative Factors
Persistent negative operating & free cash flow
The company has repeatedly burned cash and not converted reported profits into free cash flow. Persistent negative operating and free cash flow erodes reserves over months and can force external financing, constrain strategic investments, and limit the firm’s ability to scale services without diluting shareholders or increasing leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / strong equity buffer
ReproCELL’s virtually debt-free balance sheet and sizeable equity provide enduring financial flexibility, lowering solvency risk and enabling continued R&D and service operations without immediate refinancing needs. This structural capital buffer supports multi-quarter resilience during operational volatility.
Read all positive factors
ReproCELL Inc. (4978) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥12.08B
Dividend YieldN/A
Average Volume (3M)510.74K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-25.02%
EPS Growth-697.06%
CountryJP
Employees96
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.32
Shares Outstanding95,147,890
10 Day Avg. Volume504,660
30 Day Avg. Volume510,736
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.88
Price to Sales (P/S)7.46
P/FCF Ratio-34.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)¥3.53B
ReproCELL Inc. Business Overview & Revenue Model
Company Description
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, ...
How the Company Makes Money
null...
ReproCELL Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.83B | 2.23B | 2.98B | 2.43B | 2.95B | 2.23B |
| Gross Profit | 1.51B | 1.01B | 1.63B | 1.10B | 1.13B | 785.42M |
| EBITDA | -252.70M | -785.10M | -79.70M | -372.18M | -307.23M | -587.37M |
| Net Income | -125.81M | -591.69M | 103.25M | -31.41M | -305.31M | -575.10M |
Balance Sheet | ||||||
| Total Assets | 9.25B | 9.65B | 9.67B | 9.05B | 8.36B | 8.10B |
| Cash, Cash Equivalents and Short-Term Investments | 4.72B | 6.51B | 3.94B | 6.57B | 6.38B | 4.64B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 80.00M |
| Total Liabilities | 591.24M | 805.59M | 685.81M | 741.03M | 780.63M | 844.53M |
| Stockholders Equity | 8.66B | 8.85B | 8.98B | 8.31B | 7.58B | 7.25B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -481.75M | -80.40M | -182.89M | -290.92M | -289.65M |
| Operating Cash Flow | 0.00 | -383.53M | 6.29M | -11.45M | -140.53M | -246.24M |
| Investing Cash Flow | 0.00 | 57.94M | -796.00M | 404.42M | -1.09B | -2.14B |
| Financing Cash Flow | 0.00 | 0.00 | 680.11M | 544.05M | 482.87M | 2.38B |
ReproCELL Inc. Technical Analysis
Negative
143.00
Price Trends
157.64
Negative
164.12
Negative
168.16
Negative
Market Momentum
-9.27
Negative
34.37
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4978, the sentiment is Negative. The current price of 143 is above the 20-day moving average (MA) of 132.65, below the 50-day MA of 157.64, and below the 200-day MA of 168.16, indicating a bearish trend. The MACD of -9.27 indicates Negative momentum. The RSI at 34.37 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4978.
ReproCELL Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | ¥137.76B | -14.35 | ― | 2.18% | -10.48% | -1022.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.72B | -32.28 | ― | ― | -11.11% | -187.80% | |
45 Neutral | ¥17.93B | -9.59 | ― | ― | ― | 6.10% | |
43 Neutral | ¥35.24B | -10.48 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥12.08B | -20.34 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.34B | -8.15 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4978
ReproCELL Inc.
128.00
-64.00
-33.33%
JP:4593
Healios KK
255.00
-286.00
-52.87%
JP:4599
StemRIM Inc.
285.00
-70.00
-19.72%
JP:4974
Takara Bio Inc.
1,144.00
358.00
45.55%
JP:7774
Japan Tissue Engineering Co., Ltd.
595.00
-16.00
-2.62%
JP:7776
CellSeed Inc.
213.00
-302.00
-58.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.